Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Chad A Littrell und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL, United States. Hauptthemen laut MEDLINE: Dendrimers, Myeloid-Derived Suppressor Cells, Mice, Inbred C57BL. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
The focus of nanoparticles in vivo trafficking has been mostly on their tissue-level biodistribution and clearance. Recent progress in the nanomedicine field suggests that the targeting of nanoparticles to immune cells can be used to modulate the immune response and enhance therapeutic delivery to the diseased tissue. In the presence of tumor lesions, monocytic-myeloid-derived suppressor cells (M-MDSCs) expand significantly in the bone marrow, egress into peripheral blood, and traffic to the solid tumor, where they help maintain an immuno-suppressive tumor microenvironment. In this study, we investigated the interaction between PAMAM dendrimers and M-MDSCs in two murine models of glioblastoma, by examining the cell-level biodistribution kinetics of the systemically injected dendrimers. We found that M-MDSCs in the tumor and lymphoid organs can efficiently endocytose hydroxyl dendrimers. Interestingly, the trafficking of M-MDSCs from the bone marrow to the tumor contributed to the deposition of hydroxyl dendrimers in the tumor. M-MDSCs showed different capacities of endocytosing dendrimers of different functionalities in vivo. This differential uptake was mediated by the unique serum proteins associated with each dendrimer surface functionality. The results of this study set up the framework for developing dendrimer-based immunotherapy to target M-MDSCs for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL, United States.
- Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, United States.
- Department of Chemical Engineering, University of Florida College of Pharmacy, Gainesville, FL, United States.
- Department of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL, United States; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, United State…
Förderung
- NINDS NIH HHS
Zitieren
APA
Littrell, C. A., Takacs, G. P., Sankara, C. S., Sherman, A., Rubach, K. A., Garcia, J. S., Bell, C. A., Lnu, T., Harrison, J. K., & Zhang, F. (2024). Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.003
Vancouver
Littrell CA, Takacs GP, Sankara CS, Sherman A, Rubach KA, Garcia JS, et al. Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.003
BibTeX
@article{Littrell2024,
author = {Littrell, Chad A and Takacs, Gregory P and Sankara, Chenikkayala Siva and Sherman, Alexandra and Rubach, Kai A and Garcia, Julia S and Bell, Coral A and Lnu, Tejashwini and Harrison, Jeffrey K and Zhang, Fan},
title = {Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.08.003}
}
EUVIMED